While DT is not the optimal BRAF-targeted strategy for BRAFV600E CRC—producing a 7% cORR and a median PFS of 3.5 months in a previous clinical trial11—established dosing and safety data for this triple regimen from patients with melanoma allowed for more rapid initiation of this proof-of-concept clinical trial, and we reasoned that evidence of clinical cooperativity observed would provide rationale for future evaluation of ICB combinations with more effective BRAFi combinations, including anti-EGFR antibody combinations. The gene discussed is EGFR; the disease is melanoma.